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Vaccine assessment prior market authorization
A B S T R A C T
This study assessed cost-eﬀectiveness of a potential anti-tick vaccine that would protect against both Lyme
borreliosis (LB) and tick-borne encephalitis (TBE) in a highly endemic setting of Slovenia.
A Markov model was developed to estimate cost-eﬀectiveness of a vaccine with potential combined protection
against LB and TBE from the societal perspective. The model expressed time in annual cycles, followed a target
population through their lifetime, and applied an annual discounting of 3%. A target population entered the
model in a susceptible state, with time dependent probabilities to acquire LB/TBE. Disease manifestations were
either resolved within one cycle, or a patient developed LB/TBE sequelae. The vaccination consisted of initial
immunization and one revaccination. Estimates of LB/TBE direct and indirect costs, and data on natural course
of LB/TBE were obtained from Slovenian databases. Eﬀectiveness of the vaccine with potential combined pro-
tection against LB/TBE was derived from studies on existing TBE and LB vaccines, while utility estimates were
collected from various literature sources.
A vaccine with potential combined protection against LB/TBE was predicted to have an incremental cost of
€771,300 per 10,000 vaccinated persons, an incremental utility of 17QALYs and a base-case incremental cost-
eﬀectiveness ratio (ICER) of 46,061€/QALY. Vaccine cost, eﬀectiveness and discount rates were identiﬁed as the
most inﬂuential model parameters. A wholesale price for a vaccine shot of €9.13 would lead to cost savings
followed by health gains for the vaccination strategy.
The base-case ICER was below commonly accepted thresholds of cost-eﬀectiveness, indicating that a com-
bined LB/TBE vaccine might be a cost-eﬀective option in Slovenia. With early Health Technology Assessment
becoming increasingly important, this analysis still represents a rare example of cost-eﬀectiveness assessment
prior to market authorisation. Although obviously in such a situation some key parameters are unknown, our
model sets up a tool to analyse pharmacoeconomic criteria that can help development of a cost-eﬀective health
technology, in this case a combined tick-borne diseases vaccine.
1. Introduction
Lyme borreliosis (LB) and tick-borne encephalitis (TBE) are the most
common tick-borne diseases in Europe (ECDC, 2011), resulting in at
least 85,000 cases of LB and 2000–2600 cases of TBE per year (ECDC,
2011, 2014; ECDC, 2016). There are pronounced geographical diﬀer-
ences, with the annual incidence ranging from 0 to 350/100,000 and
0–22/100,000 for LB and TBE, respectively. Regions of Central and
Eastern Europe, the Baltic states and Scandinavia are the most aﬀected
(ECDC, 2016; Rizzoli et al., 2011; Süss, 2011).
In Slovenia, a small Central European country, average of 5400
cases of LB and 200 cases of TBE were reported annually in the period
2008–2014; the corresponding incidence of 260/100,000 and 10/
100,000 exceed the respective averages European estimates by 25–30
times (ECDC, 2012; Rizzoli et al., 2011; The National Public Health
Institute of the Republic Slovenia, 2018).
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LB can be successfully treated by timely antibiotic therapy.
However, a failure in the diagnosis and a delay of the treatment can
lead to more severe disease manifestations and sequelae (Stanek et al.,
2011). For TBE no etiologic treatment is available (Bogovic and Strle,
2015). A recent Slovenian study estimated that as much as 30% of TBE
patients develop sequelae, while 0.75% die due to TBE (Fafangel et al.,
2017). Sequelae can result in further outpatient visits and hospitaliza-
tions, expensive care and premature retirement, which altogether
contribute to the high costs of LB and TBE in endemic regions. As a
reference, direct annual costs of LB treatment alone were estimated at
$0.7–1.3 billion in the United States (Adrion et al., 2015). Also, the
quality of life decrement of TBE patients in Slovenia was assessed to be
167.8 disability adjusted life years (DALY) per 100,000 people, in-
dicating a high TBE disease burden in comparison to other infectious
diseases (Šmit and Postma, 2015).
In recent decades, vaccines against TBE became part of immuniza-
tion programmes in many endemic countries and established one of the
highest ﬁeld eﬀectiveness among vaccines (Kunz, 2003; Heinz et al.,
2007). In contrast, a LB vaccine was withdrawn shortly after its market
authorisation in the United States in 1998 (Poland, 2011). Currently,
two LB vaccines are in the early phase of clinical trials (Wressnigg et al.,
2013; Comstedt et al., 2014), but it is unclear whether they will reach
the market. A single vaccine that could inhibit transmission of multiple
pathogens from the tick vector to humans would be ideal. This could be
achieved by a vaccine targeting the tick rather than the individual tick-
borne pathogens. To date a tick vaccinogen for such a vaccine does not
exist. However, identiﬁcation and development of an anti-tick vaccine,
that could prevent bacterial, viral and protozoal tick-borne diseases,
including LB and TBE, has been the subject of the ongoing Anti-tick
Vaccines to Prevent Tick-borne Diseases in Europe (ANTIDotE) - project
(www.antidote-fp7.org) (Sprong et al., 2014).
Assessments of TBE or LB vaccines’ cost-eﬀectiveness have been
conducted for economic and epidemiological settings of Slovenia,
Austria, Estonia, Sweden and the United States (Askling et al., 2015;
Hsia et al., 2002; Jürisson et al., 2015; Meltzer et al., 1999; Shadick
et al., 2001; Šmit, 2012). Even though the studies varied in analysis
perspective, model structure and outcome measures, cost-eﬀectiveness
predominantly depended on disease incidence and the speciﬁc risk
distribution across age groups. Economic evaluations of vaccines (or
drugs) are often performed at the moment of market entry or even only
when explicitly considered for inclusion in a country’s immunization
program. Recently, early economic evaluation of vaccines, within the
context of early Health Technology Assessment (HTA), has become an
increasingly important step in the process of including vaccines in the
immunization programs across developed countries (Bryson et al.,
2010; Ricciardi et al., 2015). For example, the Joint Committee of
Vaccination & Immunization (JCVI) from the United Kingdom has the
horizon scanning of new vaccines yet in development embedded as a
structural component of its HTAs (Raftery, 2014). Early HTA with cost-
eﬀectiveness as a core element, is important for: (i) better under-
standing of the potential for reimbursement by the health authorities,
and marketing for the developers and producers of the vaccines, and (ii)
contributing to planning, ﬁnancing and understanding health impacts
of new vaccines for national authorities such as, for example, the
Ministry of Health and JCVI in the United Kingdom (Raftery, 2014).
This study aims to estimate cost-eﬀectiveness of a potential vaccine
with combined protection against LB/TBE in Slovenia, a country where
both LB and TBE are highly endemic. The pharmacoeconomic evalua-
tion of such a potential vaccine can be utilised as a helpful tool for both
vaccine developers and healthcare decision makers to better understand
the vaccine’s economic impact and public health value.
2. Methods
2.1. General model settings
To estimate cost-eﬀectiveness of a potential vaccine with combined
protection against LB/TBE in Slovenia, a Markov model was developed
in the statistical software R, version 3.0.2 (R Development Core Team,
2008). The model compared costs and health utilities of the current
situation with no speciﬁc prevention strategies, and vaccination of a
target population with a vaccine with potential combined protection
against LB/TBE. The analysis of the two approaches was conducted
from the societal perspective, considering direct and indirect costs.
Costs were expressed in €, and health utilities in quality adjusted life
years (QALY) gained, enabling estimates of incremental cost eﬀective-
ness ratio (ICER) measured in €/QALY as the main outcome of the
analysis. The time in the model runs in annual Markov cycles, while
total time horizon covers the average lifetime of the Slovenian popu-
lation (Statistical oﬃce of the Republic of Slovenia, 2018a). Finally,
costs and utilities estimated by the model were discounted at an annual
rate of 3%, conforming to the local pharmacoeconomic guideline
(Uradni list Republike Slovenije, 2013).
2.2. Model structure
The model synthesized natural courses of LB and TBE through
clinically relevant stages of the diseases, deﬁned as mutually exclusive
Markov health states (Fig. 1A and B). Both compared cohorts entered
the model at age 18, the youngest age eligible for LB/TBE vaccination,
and were followed until the age of 81, which corresponded to an ex-
pected life length in Slovenia (Statistical oﬃce of the Republic of
Slovenia, 2018a). Patients moved through the model states in ac-
cordance with transition probabilities (Table 1) that were estimated
from data of the National Institute of Public Health of the Republic of
Slovenia and/or a register of Lyme borreliosis Outpatient Clinic (LBOC)
of the University Medical Centre Ljubljana (The National Public Health
Institute of the Republic Slovenia, 2018; Data available at LBOC, 2018).
At the beginning cohorts were in a health state “Susceptible” where
they could remain, contract LB and/or TBE according to speciﬁc time
dependent probabilities for these diseases (p_LB, p_TBE), or die.
Patients who develop LB do not gain a permanent immunity (Stanek
et al., 2011); thus, all such patients moved back to the susceptible state
in the Markov model. In contrast, patients who acquired TBE were in-
terpreted to have a life-long protection (Data available at LBOC, 2018).
LB and TBE were represented by two periods, active disease and
sequelae. The speciﬁc manifestations of active LB were: erythema mi-
grans (EM), which could be solitary or multiple, borrelial lymphocy-
toma (BL), Lyme neuroborreliosis (LNB), Lyme carditis (LC), Lyme ar-
thritis (LA) and acrodermatitis chronica atrophicans (ACA). The
manifestations of active TBE were: meningitis (Me), moderately severe
meningoencephalitis (modME), severe meningoencephalitis and me-
ningoencephalomyelitis (sevME), and hospitalization in intensive care
unit due to TBE (TBE ICU). In our model, all listed disease manifesta-
tions were interpreted as transitory and were either resolved within one
year, or patients proceeded to sequelae of LB/TBE (Fig. 1A and B).
Sequelae were deﬁned as symptoms/signs present one year after
diagnosis and treatment of LB or TBE. Sequelae of LB were speciﬁed as
EM, LNB, ACA and LA sequelae. Since available Slovenian data sources
suggested that LC and BL are very rare and infrequently result in se-
quelae (Data available at LBOC, 2018) these manifestations were in-
terpreted as not developing long-term conditions. Recovery from the
sequelae was allowed in the model to fully capture the complexity of
the disease. According to detailed follow-up data (Data available at
LBOC, 2018) 50% of patients with EM, 25% with LNB, 20% with LA,
and 10% with ACA who had LB sequelae fully recover within 5 years
(Table 1). Unlike LB, none of the patients with TBE sequelae (speciﬁed
as Me, modME and sevME sequelae) were expected to fully recover in
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the model (Data available at LBOC, 2018); they were only redistributed
from more to less severe TBE sequelae (Fig. 1A and B, Table 1).
Finally, death from any cause was possible from any of the Markov
states and equal to the age-dependent natural mortality rate in Slovenia
(Statistical Oﬃce of the Republic of Slovenia, 2018a). Disease-speciﬁc
mortality was ascribed only to TBE sequelae state and estimated at
2.3% for TBE patients older than 60 years (Logar et al., 2006). All time
dependent probabilities used in the model have been presented in the
table of Supplemental material 1.
2.3. Vaccination
Vaccination aﬀected the vaccinated cohort within the model only in
lowering probabilities of contracting LB/TBE (p_LB_v, p_TBE_v in
Fig. 2B). The model allowed selection of diﬀerent vaccination coverages
and accordingly modiﬁed probabilities of contracting LB/TBE. Persons
who acquired disease despite the vaccination were interpreted to have
the same probabilities for disease progression as those not vaccinated.
No herd immunity was assumed.
As the subject of this study was a potential vaccine, its main para-
meters, costs and eﬀectiveness, were unknown and they had to be as-
sumed. To cope with this uncertainty, several scenarios with diﬀerent
costs and eﬀectiveness of the vaccine were analysed.
In the base case analysis, we assumed a cost of €50 for a dose of a
potential LB/TBE vaccine and a schedule consisting of one initial ad-
ministration and one booster three years later. Our estimate of the
vaccine costs was conservatively based on current cost of an existing
TBE vaccine in Slovenia (Šmit, 2012) multiplied by two. We chose a
two vaccine dose scenario because all published cost-eﬀectiveness and
most of eﬀectiveness studies on LB/TBE vaccines reported their out-
comes after two or maximum three vaccine shots (Hsia et al., 2002;
Shadick et al., 2001; Šmit, 2012). However, an extensive set of diﬀerent
vaccination schedules has been tested in a sensitivity analysis (5 dif-
ferent scenarios with total of 3–18 vaccine shots per lifetime).
Fig. 1. A) Model scheme without the vaccination. B) Model scheme with the vaccination.
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Table 1
List of input parameters.
Parameter Base case value Range used in sensitivity analysis1 Reference
Vaccination
Vaccination population coverage 100% 80–100%; a special scenario includes coverage of
12.4%, recorded for TBE vaccination in Slovenia ;
Assupmtion, Grgič-Vitek and Klavs,
2011
Vaccination schedule 2 shots (ﬁrst year) in total several special scenarios in sensitivity analysis Assumption
Cost of a vaccine shot € 50 €40–60 Assupmtion
Eﬀectiveness of a vaccine against
LB
85.00% 74.00–86.00 % (within 95% CI) Shadick et al., 2001
Eﬀectiveness of a vaccine against
TBE
98.70% 97.98%–99.09% (within 95% CI) Heinz et al., 2007
Time parameters
Time horizon 64 annual cycles (from age 18 till age 81) 51–77 Statistical oﬃce of the Republic of
Slovenia, 2018a
Discount rate for costs/
eﬀectiveness
3.0% 2.4–3.6% (+several special scenarios) Uradni List Republike Slovenije,
2013
Model probabilities
Probability of contracting LB (any
form)
0.00009–0.000303
(detailed age-depenent data provided in
Appendix)
± 20% The National Public Health
Institute of the Republic Slovenia,
2018
Probability of contracting TBE
(any form)
0.0000151–0.0000353
(detailed age-depenent data provided in
Appendix)
± 20% The National Public Health
Institute of the Republic Slovenia,
2018
Probability of natural death 0.00039–0.05814 (detailed age-depenent
data provided in Appendix)
± 20% Statistical oﬃce of the Republic of
Slovenia, 2018a
TBE speciﬁc mortality age-dependent, 0% age18–60, 2.3% >60 ±20% Logar et al., 2006
Proportion of EM pt among LB pt 0.90000 0.72000–1.00000 Data available at LBOC, 2018
Proportion of LNB pt among LB pt 0.07730 0.06184–0.09276 Data available at LBOC, 2018
Proportion of ACA pt among LB pt 0.07890 0.06312–0.09276 Data available at LBOC, 2018
Proportion of BL pt among LB pt 0.00640 0.00512–0.00768 Data available at LBOC, 2018
Proportion of LA pt among LB pt 0.03390 0.02712–0.04068 Data available at LBOC, 2018
Proportion of LC pt among LB pt 0.00320 0.00256–0.00384 Data available at LBOC, 2018
Proportion of Me pt among TBE pt 0.34400 0.27520–0.41280 Bogovic et al., 2014
Proportion of modME among TBE
pt
0.46500 0.37200–0.55800 Bogovic et al., 2014
Proportion of sevME among TBE
pt
0.19100 0.15280–0.22920 Bogovic et al., 2014
Proportion of EM sequelae that
proceeds from EM
0.08000 0.06400–0.09600 Data available at LBOC, 2018
Proportion of LNB sequelae that
proceeds from LNB
0.12000 0.09600–0.14400 Data available at LBOC, 2018
Proportion of ACA sequelae that
proceeds from ACA
0.55000 0.44000–0.66000 Data available at LBOC, 2018
Proportion of LA sequelae that
proceeds from LA
0.15000 0.12000–0.18000 Data available at LBOC, 2018
Proportion of Me sequelae that
proceeds from Me
0.52620 0.42096–0.63144 Data available at LBOC, 2018
Proportion of modME sequelae
that proceeds from modME
0.09250 0.07400–0.11100 Data available at LBOC, 2018
Proportion of sevME sequelae that
proceeds from sevME
0.50260 0.40208–0.60312 Data available at LBOC, 2018
Proportion of pt with TBE
requiering ICU treatment
0.03000 0.02400–0.03600 Data available at LBOC, 2018
Proportion of EM sequelae that
fully recovers
0.50000 0.40000–0.60000 Assupmtion
Proportion of LNB sequelae that
fully recovers
0.25000 0.20000–0.30000 Assupmtion
Proportion of ACA sequelae that
fully recovers
0.10000 0.08000–0.12000 Assupmtion





Cost of treating EM € 313.00 €250.40–375.60 Data available at LBOC, 2018
Cost of treating EM sequelae € 31.00 €24.80–37.20 Data available at LBOC, 2018
Cost of treating BL € 676.00 €540.80–811.20 Data available at LBOC, 2018
Cost of treating ACA € 1591.00 €1272.80–1,909.20 Data available at LBOC, 2018
Cost of treating ACA sequelae € 110.00 €88.00–132.00 Data available at LBOC, 2018
Cost of treating LNB € 4328.00 €3462.40–5,193.60 Data available at LBOC, 2018
Cost of treating LNB sequelae € 118.17 €94.54–141.80 Data available at LBOC, 2018
Cost of treating LC € 4876.00 €3900.80–5,851.20 Data available at LBOC, 2018
Cost of treating LA € 480.00 €384.00–576.00 Data available at LBOC, 2018
Cost of treating LA sequelae € 480.00 €384.00–576.00 Data available at LBOC, 2018
Cost of treating Me € 1235.00 €988.00–1,480.00 Data available at LBOC, 2018
Cost of treating modME € 2915.00 €2332.00–3,498.00 Data available at LBOC, 2018
(continued on next page)
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Another important assumption was made for the vaccine eﬀective-
ness. As there were no data on the eﬀectiveness of a potential vaccine
with combined protection against LB/TBE, in the base case analysis we
ascribed reported eﬀectiveness rates estimated separately for (old) LB
and TBE monovalent vaccines. The 98.7% ﬁeld eﬀectiveness reported
for TBE vaccine (Heinz et al., 2007) was used as an eﬀectiveness rate
against TBE in a potential vaccine. Information on LB vaccines, which
was much scarcer and mostly limited to 2–3 year follow-up periods,
indicated eﬀectiveness rate between 62% and 85% (Shadick et al.,
2001). The latter was used as an eﬀectiveness rate in our base case
analysis, while the former was tested in the sensitivity analysis, to-
gether with lower and upper conﬁdence intervals of all reported ef-
fectiveness rates against LB and TBE.
2.4. Costs and utilities estimates
All costs in the model were collected from the local Slovenian
sources and expressed in 2016 € (Table 1). Each of the deﬁned Markov
health states had an annual estimate of direct costs based on the local
Slovenian data. To get LB and TBE speciﬁc indirect costs, the proportion
of days lost due to LB or TBE (48 and 4.35 days for TBE and LB, re-
spectively (Bogovič, 2012; Data available at LBOC, 2018)) was multi-
plied by the average yearly salary (Statistical oﬃce of the Republic of
Slovenia, 2018b).
To express health beneﬁts in QALYs, the model required separate
estimates of health utilities per each deﬁned Markov state (Table 1).
While quality of life of most of the LB and TBE states could be described
with the estimates from published sources (Shadick et al., 2001; Šmit,
2012), there were no data on ACA and BL. Conservatively, we assigned
utilities of the least damaging LB state, i.e. EM, to both ACA and BL.
2.5. Sensitivity analysis
Univariate sensitivity analysis (SA) was conducted by varying each
of the 64 input parameters in the model± 20% or, when possible,
within established 95% conﬁdence intervals to ascertain their impact
on the main cost-eﬀectiveness estimate (ICER). As 62 of 64 parameters
presented point estimates without available 95% conﬁdence intervals
(Table 1), a simultaneous variation of all parameters within their±
20% ranges through a standard probabilistic sensitivity analysis would
result in potentially imprecise outcomes. Notably, potential probabil-
istic sensitivity analysis would create conﬁdence intervals around the
base case cost-eﬀectiveness estimate that would predominantly depend
on the arbitrary selected range of input parameters, leading to non-
informative uncertainty estimates. Therefore, the impact of the most
uncertain parameters was additionally tested outside the predeﬁned
parameter ranges through the scenario analyses. The most uncertain
parameters included the schedule of vaccination (5 scenarios), vaccine
eﬀectiveness rates (1 scenario for LB vaccine eﬀectiveness), costs of a
potential LB/TBE vaccine (3 scenarios), discount rates (3 scenarios),
indirect costs (1 scenario), TBE mortality (1 scenario) and time horizon
of the analysis (1 scenario). More detailed description of all listed
scenarios is provided in Table 2.
3. Results
3.1. Base case
A potential vaccination with an anti-tick vaccine that would com-
bine protection against LB and TBE in Slovenia resulted in a total costs
estimate of €95.10 per person, while the current “no vaccination”
strategy equalled to €17.97 per person (Table 3). Of the total costs per
person in the vaccinated population, €94.35 went to the costs of vac-
cines and only €0.75 per person to the treatment of LB/TBE that oc-
curred despite vaccination. As all costs in non-vaccinated population
related to the LB/TBE treatment costs, the vaccine prevented €17.22 of
€17.97 treatment costs. Incremental costs required to introduce a po-
tential LB/TBE vaccination was estimated at €77.13 per person
(Table 3). Main utilities’ estimates in the base case setting were 25.9962
QALY and 25.9946 QALY per person for vaccinated and non-vaccinated
populations. The vaccination lowered time spent in disease and se-
quelae phases of LB/TBE, which led to total utilities increase estimated
at 0.0017 QALY per each person in the vaccinated population and a
base case ICER at €46,061/QALY (Table 3).
Table 1 (continued)
Parameter Base case value Range used in sensitivity analysis1 Reference
Cost of treating sevME € 11,100.00 €8880.00–13,320.00 Data available at LBOC, 2018
Cost of treatment in ICU € 20,400.00 €16,320.00–24,480.00 Data available at LBOC, 2018
Cost of treating Me sequelae € 70.00 €56.00–84.00 Data available at LBOC, 2018
Cost of treating modME sequelae € 122.00 €97.60–146.40 Data available at LBOC, 2018
Cost of treating sevME sequelae € 28,592.00 €22,873.60–34,310.40 Data available at LBOC, 2018
Indirect costs
Average gross monthly salary in
Slovenia
€ 1687.00 €1349.60–2,024.40 Statistical oﬃce of the Republic of
Slovenia, 2018b
Average number of work absence
days due to TBE
48 38.40–57.60 Bogovič, 2012
Average number of work absence
days due to LB
4.35 3.48–5.22 Data available at LBOC, 2018
Utilities
1Utility of EM 0.800 0.960–0.640 Shadick et al., 2001
5Utility of LA 0.690 0.552–0.828 Shadick et al., 2001
4Utility of LC 0.610 0.488–0.732 Shadick et al., 2001
3Utility of LNB 0.520 0.416–0.624 Shadick et al., 2001
6Utility of ACA 0.800 0.640–0.960 Assumption
2Utility of BL 0.800 0.640–0.960 Assumption
Utility of Me 0.977 0.782–1.000 Šmit, 2012
Utility of modME 0.840 0.672–1.000 Šmit, 2012
Utility of sevME 0.371 0.297–0.445 Šmit, 2012
Utility of ICU 0.190 0.152–0.228 Šmit, 2012
Abbreviations: LB – Lyme Borreliosis; TBE – tick borne encephalitis; EM – Erythema migrans; LNB – Lyme neuroborreliosis; ACA – Acrodermatitis chronica atro-
picans; BL – Borrelial lymphocytoma; LA – Lyme arthritis; LC - Lyme carditis; Me – Meningitis; modME – moderately severe meningoencephalitis; sevME – severe
meningoencephalitis and meningeoencephalomyelitis; ICU – intensive care unit.
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3.2. Sensitivity analysis
Parameters and predeﬁned scenarios aﬀecting the base case ICER by
more than €1,000/QALY are shown in Fig. 2 and in the details in the
table of Supplemental material 2.
Changes to the vaccination schedule would have the greatest impact
on the ICER. Notably, in the scenario with 18 vaccine shots during a
person’s lifetime, the ICER increases from €46,061/QALY to €246,456/
QALY. Vaccination every 5 years, every 10 years or only 3 times in total
would result in ICERs of €163,117/QALY, €85,280/QALY and
€75,921/QALY, respectively. Comparably important parameters seem
to be discount rates and utility value of the EM state. Variation± 20%
of utility of EM changed ICER from €86,409/QALY to €31,400/QALY.
Discounting of both costs and utilities at 5% would increase ICER to
€85,775/QALY, while no discounting would result in an ICER at
€10,301/QALY. Diﬀerential discounting of costs at 4% and utilities at
1.5% led to an ICER of €28,709/QALY. All other parameters/scenarios
aﬀected the ICER to a considerably smaller extent (Fig. 2, Supplemental
material 2).
Using the presented cost-eﬀectiveness model, it was possible to
establish vaccine prices needed to achieve certain predeﬁned cost-ef-
fectiveness levels under base case values of all other parameters
(Table 4). A price of a vaccine shot set at €55.71 would enable cost-
eﬀective ICER according to the World Health Organisation merits
(WHO Commission on Macroeconomics and Health, 2001), which
equals to 3 GDP/c or 52,500/QALY in Slovenia (Statistical oﬃce of the
Republic of Slovenia, 2018b). The vaccination would be considered a
very cost-eﬀective option with an ICER at 1 GDP/c or €17,500/QALY if
the vaccine would cost €24.66. Finally, keeping all other parameters
ﬁxed at the base case value, a vaccine cost of €9.13 would render the
vaccination against LB/TBE pharmacoeconomically dominant in com-
parison to no vaccination strategy, meaning that it would result in
health gains followed by cost savings.
4. Discussion
The present study assessed cost-eﬀectiveness of a potential vacci-
nation against LB and TBE with a single anti-tick vaccine in a highly
endemic setting of Slovenia. For the ﬁrst time, it synthesizes natural
courses of LB and TBE in a single mathematical model substantiated
Fig. 2. Tornado diagram.
Abbreviations used for parameters/scenarios in Fig. 2: full_vac(18x) - full vaccination scenario considers 18 vaccine shots; vacc_5y - vaccination each 5 years; U_EM -
utility of state Erythema migrans (EM); disc_5% - discounting costs and utilities at 5%; vacc_10y - vaccination each 10 years; disc_0% - no discounting of costs and
utilities; vacc_3x - 3 vaccine shots during ﬁrst year followed with no vaccination after that; disc_4%/1.5% - discounting of costs at 4% and utilities at 1.5%; p_EM -
proportion of EM patients among Lyme borreliosis (LB) patients; U_Me - utility of state Meningitis; LB_vacc_EFF.62% - vaccine eﬀectiveness against LB set at 62%;
C_vacc - cost of vaccine; mor_TBE.1.5% - mortality of TBE set at 1.5% for all ages; tot_cyc - total number of cycles in the model; vacc_25y - vaccination each 25 years;
p_LB - probability of contracting LB; U_ACA - utility of state Acrodermatitis chronica atrophicans (ACA); w_o_Ind_c - scenario without indirect costs included;
w_o_Ind_cTBE - scenario without indirect costs for tick-borne encephalitis (TBE); LB_vacc_EFF - vaccine eﬀectiveness against LB; tot_cyc83 - scenario with the model
lasting 83 cycles; p_EMch - proportion of patients with EM that have sequalae; p_nd - probability of natural death; p_ACAch - proportion of patients with ACA that
have seqalae; U_LNB - utility of state Lyme neuroborreliosis; p_sevMEch - proportion of patients with severe meningoencephalitis (sevME) that have sequalae; p_Mech
- proportion of patients with meningitis that have sequalae; p_sevME - proportion of patients with sevME among patients with TBE; av_sal - avarage annual salary in
Slovenia; abs_d_TBE - annual number of days absent from work due to TBE.
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with the high quality epidemiological data, and provides a framework
for eﬀectiveness/cost-eﬀectiveness examination of future preventive/
curative approaches that would target these tick-borne diseases. It is
one of the rare studies to examine health economics of an upcoming
preventive strategy on which main parameters, such as a vaccine cost
and eﬀectiveness, are still unknown.
Cost-eﬀectiveness evaluations of the monovalent TBE vaccine con-
sidered the vaccine cost-eﬀective in Slovenia, Austria and Estonia with
ICERs between €15,000 and €61,000/QALY, while it was judged as not
cost-eﬀective for Sweden (Askling et al., 2015; Jürisson et al., 2015;
Šmit, 2012). All three studies on LB vaccine from the United States
suggest that in highly endemic regions the LB vaccine would prove
more cost-eﬀective than in regions with lower LB incidence (Hsia et al.,
2002; Meltzer et al., 1999; Shadick et al., 2001). However, only one of
the studies estimated cost-eﬀectiveness through the generically com-
parable outcome of $/QALY, reported ICER of $62,300/QALY
(∼54,000 €/QALY)and considered the vaccine to be cost-eﬀective
(Meltzer et al., 1999).
It has been estimated that a potential LB/TBE vaccine, as deﬁned in
the present study, would bring 0.0017 QALY per person in the whole
Slovenian population for an investment of €77.13 per person, leading to
the cost-eﬀectiveness estimate of €46,061/QALY. This makes the LB/
TBE vaccination a cost-eﬀective strategy in Slovenia according to the
criteria of WHO (WHO Commission on Macroeconomics and Health,
2001). However, several major uncertainties exist, that are pre-
dominantly inherent to the early state of vaccine development in which
this study was undertaken. Diﬀerent vaccine schedules and varying
discount rates resulted in particularly large variations in the ICER. Since
the ﬁnal vaccine schedule could be established only years after the
vaccine’s authorisation, we tested a wide range of schedules (2–18
shots) that resulted in ﬁve-fold diﬀerent ICERs (€46,000–€250,000/
QALY).
Discounting is a more general problem in a long-term cost-eﬀec-
tiveness modelling of which a vaccination is a typical example. As most
preventive strategies incur costs immediately and bring beneﬁts later
during a lifetime period, lower discounting of health beneﬁts presents
more favourable cost-eﬀectiveness results. In our study a discounting
range from 0 to 5% changed the ICER from €10,000/QALY (highly cost-
eﬀective) to €85,000/QALY (not cost-eﬀective). It is debatable whether
the base-case discount rates of 3% for costs and utilities applied in this
analysis (Uradni list Republike Slovenije, 2013) accurately address
people’s preferences for costs and beneﬁts. Namely, a recent critical
review on discounting in 84 cost-eﬀectiveness studies of diﬀerent vac-
cines suggested that lowering and delay of discount rates, or diﬀerential
discounting (higher for costs than for utilities) may lead to more rea-
listic cost-eﬀectiveness estimates (Jit and Mibei, 2015).
One of the main purposes of the presented analysis was to inform
the anti-tick vaccine developers and manufacturers on thresholds of
vaccine price and eﬀectiveness that would lead to an acceptable cost-
eﬀectiveness for the vaccination strategy in an endemic setting, such as
Slovenia. If a potential anti-tick vaccine achieves the eﬀectiveness of
separate TBE and LB vaccines, price that leads to a favourable cost-
eﬀectiveness ranges between €25 and €50 per shot, and prices below €9
provide cost savings. On the other hand, failure to achieve cited ef-
fectiveness rates against LB and TBE or potential improvement beyond
these rates, would accordingly change the pricing frame for a potential
anti-tick vaccine. Finally, due to relatively higher incidence of LB in
comparison to TBE, the model outlined eﬀectiveness against LB as
much more inﬂuential for cost eﬀectiveness of a potential LB/TBE
vaccine.
Since the major cause of uncertainty in our study concerns its hy-
pothetical nature, with exact costs and eﬀectiveness of the vaccine still
being core unknown variables, all ﬁndings should be interpreted with
caution and understanding of the parameters’ uncertainty. Nonetheless,
we note that the study provides a valuable tool for future health tech-
nology evaluations with a comprehensive and ﬂexible model that can
Table 2
List of special scenarios conducted in the analysis.
Parameter (number of
scenarios)
Description of a parameter in each of special scenarios
Vaccination schedule (5) 3 vaccine shots in ﬁrst year followed by a shot each 5
years (until the age of 60), then each 3 years (18 shots
in total)
1 vaccine shot each 5 years
1 vaccine shot each 10 years
1 vaccine shot each 25 years
3 vaccine shots in the ﬁrst year
Vaccine eﬀectiveness
against LB (1)
lower eﬀectiveness rate from the literature (62%)
Vaccine price (3) vaccine price that provides cost-eﬀectiveness
(ICER< €52,500/QALY)
vaccine price that provides high cost-eﬀectiveness
(ICER< €17,500/QALY)
vaccine price that provides pharmacoeconomic
dominance (C≤ 0, E > 0, ICER≤ 0)
Discount rates (3) discount rates at 5%
discount rates at 4%
diﬀerential discounting (4% for costs and 1.5% for
utilities)
Indirect costs (1) indirect costs excluded
TBE mortality (1) TBE mortality of 1.5% for all ages
Time horizon time horizon prolonged to 100 years
Table 3
Base case cost-eﬀectiveness results1.
Outcome Vaccination arm No intervention arm
Costs [€]:
Vaccination cost 94.35 0.00
Treatment cost of LB disease 0.42 2.80
Treatment cost of LB sequelae 0.06 0.42
Treatment cost of TBE disease 0.02 1.79
Treatment cost of TBE sequelae 0.04 3.00
Indirect costs (absenteesm) 0.20 9.95
Total costs per person [€] 95.10 17.97
Diﬀerence in costs (Vacc.-No Interv.) 77.13
Utilities [QALY]:
Obtained in state susceptable 25.9951 25.9768
Obtained in LB disease 0.0007 0.0049
Obtained in LB sequelae 0.0002 0.0016
Obtained in TBE disease 0.0001 0.0079
Obtained in TBE sequelae 0.0000 0.0033
Total utilities per person [QALY] 25.9962 25.9946
Diﬀerence in utilities (Vacc-No Interv) 0.0017
Incremental cost eﬀectiveness ratio
[€/QALY]
46,061
Legend – 1-Base case concerns the set of all input parameters at their main
values as provided in second column of Table 1.
Table 4
Determination of a vaccine price required to achieve diﬀerent cost-eﬀectiveness
levels.
Cost-eﬀectiveness level ICER [€/QALY] Price of a vaccine shot
[€]
Base case 46,061 50.00
Vaccination being cost-eﬀective1 52,500 55.71








Legend: 1-according to the WHO a limit for cost-eﬀectiveness is 3 GDP/capita -
52,500€/QALY in Slovenia; 2-according to the WHO a limit for high cost-ef-
fectiveness is 1GDP/capita - 17,500€/QALY; 3-pharmacoeconomic dominance
of an intervention relates to the situation when an intervention delivers addi-
tional health beneﬁts followed by reduction of costs.
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be utilised in pre-registration phase of any combined LB/TBE preven-
tion strategy, and with the ability to support and enhance the under-
standing of the reimbursement potentials of the combined vaccine to
the developer, producer and authorities.
The present study also has several other limitations. For example,
there is a lack of (reliable) data on 5-year recovery rates from LB se-
quelae. Therefore, we relied on the best estimates of experienced clin-
ical experts (Data available at LBOC, 2018).
To conclude, we analysed the cost-eﬀectiveness of a potential anti-
tick vaccine that would combine protection against LB and TBE in
Slovenia. Inherent to early HTA, some key parameters were unknown.
Yet, the model provides a tool to analyse health economics of any future
LB/TBE vaccination strategy in highly endemic regions for one or both
diseases, advices authorities in planning immunization programs and
provides the insights into potential price/eﬀectiveness combinations
that could be feasible and attractive to both the manufacturers and the
authorities. The base-case ICER was below commonly accepted
thresholds of cost-eﬀectiveness, indicating that a potential LB/TBE
vaccine might be a cost-eﬀective option in Slovenia under speciﬁc as-
sumptions for these key parameters. The results should be taken with
caution, as they are prone to signiﬁcant structural and parameter un-
certainty which is again inherent to the early-HTA context in which we
analysed the potential vaccine.
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